<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02684071</url>
  </required_header>
  <id_info>
    <org_study_id>NCH-CNS-1601</org_study_id>
    <nct_id>NCT02684071</nct_id>
  </id_info>
  <brief_title>Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors</brief_title>
  <official_title>A Phase II Study of Intraventricular Methotrexate With Systemic Topotecan and Cyclophosphamide in Children With Recurrent or Progressive Malignant Brain Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicklaus Children's Hospital f/k/a Miami Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nicklaus Children's Hospital f/k/a Miami Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to test an experimental treatment method for recurrent
      or progressive brain tumors in children aged from 0-22 years. The use of methotrexate and
      chemotherapy (topotecan and cyclophosphamide) is experimental in this study. This means that
      their use by themselves or together has not been approved by the U.S. Food and Drug
      Administration for this usage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this research study is to test an experimental treatment method for recurrent
      or progressive brain tumors in children aged from 0-22 years. The use of methotrexate and
      chemotherapy (topotecan and cyclophosphamide) is experimental in this study. This means that
      their use by themselves or together has not been approved by the U.S. Food and Drug
      Administration for this usage. This study will attempt to determine via serial MRI scans if
      methotrexate administration into the lateral or fourth ventricle in combination with systemic
      intravenous topotecan and cyclophosphamide is effective in reducing tumor burden in the brain
      and spine for patients with recurrent or progressive brain tumors, including medulloblastoma,
      ependymoma, PNET (Primitive Neuroectodermal Tumor), atypical teratoid/rhabdoid tumor (AT/RT),
      and other malignant embryonal tumors. In addition, the study will evaluate the toxicity of
      the above mentioned experimental treatment during a two-year progression-free survival and
      survival of children with recurrent malignant brain tumors.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response</measure>
    <time_frame>6 months</time_frame>
    <description>MRI response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity of chemotherapy regimen (topotecan and cyclophosphamide)</measure>
    <time_frame>6 months</time_frame>
    <description>Laboratory results, MRI, physical examination</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Recurrent Childhood Medulloblastoma</condition>
  <condition>Recurrent Childhood Ependymoma</condition>
  <condition>Childhood Atypical Teratoid/Rhabdoid Tumor</condition>
  <condition>Embryonal Tumor With Abundant Neuropil and True Rosettes</condition>
  <condition>Metastatic Malignant Neoplasm to the Leptomeninges</condition>
  <arm_group>
    <arm_group_label>Intra thecal methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IT methotrexate via Ommaya reservoir with concomitant systemic topotecan and cyclophosphamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intra thecal methotrexate</intervention_name>
    <description>IT methotrexate via Ommaya reservoir with concomitant systemic topotecan and cyclophosphamide</description>
    <arm_group_label>Intra thecal methotrexate</arm_group_label>
    <other_name>Intra thecal methotrexate, topotecan and cyclophosphamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan</intervention_name>
    <description>To be administered in conjunction with methotrexate</description>
    <arm_group_label>Intra thecal methotrexate</arm_group_label>
    <other_name>Intra thecal methotrexate, topotecan and cyclophosphamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>To be administered in conjunction with methotrexate and topotecan</description>
    <arm_group_label>Intra thecal methotrexate</arm_group_label>
    <other_name>Intra thecal methotrexate, topotecan and cyclophosphamide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recurrent or progressive supratentorial or posterior fossa tumors with measurable
             disease on imaging studies of the brain and spine or CSF cytology.

          -  Tumor histology, including: Medulloblastoma , PNET, or other embryonal tumor, Atypical
             teratoid/rhaboid tumor (AT/RT), and Ependymoma.

          -  Leptomeningeal dissemination of a previously diagnosed CNS tumor.

          -  Diagnosis of tumor pathology will be based upon pathology diagnosis from previous
             surgeries for patients with recurrent tumors.

          -  Patients must have received prior radiation before current recurrence, unless the
             patient is less than 36 months old at diagnosis and has progressed after at least one
             upfront chemotherapy regimen in which case no prior radiation is required.

          -  Patients must have a life expectancy of at least 12 weeks as indicated by the
             patient's oncologist and/or neurosurgeon.

          -  Lansky or Karnofsky Performance status of at least 50.

          -  Negative pregnancy test.

          -  Specific organ function requirements for: Central Nervous System, Bone Marrow, renal
             and liver.

        Exclusion Criteria:

          -  Patients that do not meet the inclusion criteria above.

          -  Pregnant or lactating female patients.

          -  Patients currently enrolled in another experimental treatment protocol.

          -  Patients with documented allergies to any of the chemotherapy agents used in this
             study.

          -  Patient/Parent refuses study participation.

          -  Patient is severely somnolent or comatose.

          -  Unable or unwilling to commit to return or to follow-up visits.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>22 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ziad Khatib, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nicklaus Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ziad Khatib, MD</last_name>
    <phone>305-662-8360</phone>
    <email>ziad.khatib@mch.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jenny Esteves</last_name>
    <phone>786-624-2854</phone>
    <email>jenny.esteves@mch.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nicklaus Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ziad A Khatib, MD</last_name>
      <phone>305-662-8386</phone>
      <email>ziad.khatib@mch.com</email>
    </contact>
    <contact_backup>
      <last_name>Matthew Bittle, Supervisor</last_name>
      <phone>786-624-2838</phone>
      <email>matthew.bittle@nicklaushealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>John Ragheb, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillermo De Angulo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sanjiv Bhatia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Toba Niazi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Sandberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Diaz, ARNP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ziad A Khatib, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.nicklauschildrens.org/medical-services/cancer-center.aspx</url>
    <description>Nicklaus Children's Hospital Cancer Center</description>
  </link>
  <reference>
    <citation>Gururangan S, Petros WP, Poussaint TY, Hancock ML, Phillips PC, Friedman HS, Bomgaars L, Blaney SM, Kun LE, Boyett JM. Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). Clin Cancer Res. 2006 Mar 1;12(5):1540-6.</citation>
    <PMID>16533779</PMID>
  </reference>
  <reference>
    <citation>Slavc I, Schuller E, Czech T, Hainfellner JA, Seidl R, Dieckmann K. Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination. J Neurooncol. 1998 Jun-Jul;38(2-3):213-8.</citation>
    <PMID>9696374</PMID>
  </reference>
  <reference>
    <citation>Yoshimura J, Nishiyama K, Mori H, Takahashi H, Fujii Y. Intrathecal chemotherapy for refractory disseminated medulloblastoma. Childs Nerv Syst. 2008 May;24(5):581-5. Epub 2007 Dec 5.</citation>
    <PMID>18057943</PMID>
  </reference>
  <reference>
    <citation>Sandberg DI, Solano J, Petito CK, Mian A, Mou C, Koru-Sengul T, Gonzalez-Brito M, Padgett KR, Luqman A, Buitrago JC, Alam F, Wilkerson JR, Crandall KM, Kuluz JW. Safety and pharmacokinetic analysis of methotrexate administered directly into the fourth ventricle in a piglet model. J Neurooncol. 2010 Dec;100(3):397-406. doi: 10.1007/s11060-010-0210-0. Epub 2010 May 4.</citation>
    <PMID>20440538</PMID>
  </reference>
  <reference>
    <citation>Sandberg DI, Crandall KM, Koru-Sengul T, Padgett KR, Landrum J, Babino D, Petito CK, Solano J, Gonzalez-Brito M, Kuluz JW. Pharmacokinetic analysis of etoposide distribution after administration directly into the fourth ventricle in a piglet model. J Neurooncol. 2010 Mar;97(1):25-32. doi: 10.1007/s11060-009-9998-x. Epub 2009 Aug 18.</citation>
    <PMID>19688296</PMID>
  </reference>
  <results_reference>
    <citation>Sandberg DI, Crandall KM, Petito CK, Padgett KR, Landrum J, Babino D, He D, Solano J, Gonzalez-Brito M, Kuluz JW. Chemotherapy administration directly into the fourth ventricle in a new piglet model. Laboratory Investigation. J Neurosurg Pediatr. 2008 May;1(5):373-80. doi: 10.3171/PED/2008/1/5/373.</citation>
    <PMID>18447671</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2016</study_first_submitted>
  <study_first_submitted_qc>February 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2016</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nicklaus Children's Hospital f/k/a Miami Children's Hospital</investigator_affiliation>
    <investigator_full_name>Ziad Khatib</investigator_full_name>
    <investigator_title>Director of Neuro-Oncology</investigator_title>
  </responsible_party>
  <keyword>medulloblastoma, ependymoma, AT/RT, embryonal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Rhabdoid Tumor</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Meningeal Carcinomatosis</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

